GHK-Cu Non-Responder Profile: Who Doesn't Respond and Why

Is there a defined non-responder profile?

The actions credited to GHK-Cu (stimulated collagen and proteoglycan production, metalloproteinase modulation, and attraction of immune and endothelial cells to injured tissue) come from laboratory and animal work summarized by the researchers who proposed them [6]. These are proposed mechanisms, not proven human effects. A 2026 systematic review that screened 1,247 records and kept 64 called the human literature thin and fragmented, with most randomized trials small and run on facial cosmetic creams [7].

What the two trials found

After CO2 laser resurfacing. Skin around the mouth was resurfaced with a CO2 laser, then patients were randomized to post-treatment care with or without GHK-Cu; 13 completed the study. Computer analysis and blinded evaluators found no significant difference between groups in how quickly redness resolved, in wrinkles, or in overall skin quality, and all patients improved. On a validated questionnaire, the GHK-Cu group reported greater improvement in overall skin quality (P=.04) [1].

Venous stasis ulcers. Eighty-six evaluable patients completed the trial. The 0.4% tripeptide copper complex cream was no different from the inert vehicle placebo on ulcer size, while silver sulfadiazine 1% reduced ulcer size [2].

Copper status, genetics and photoaging

Neither trial's published abstract reports whether copper status, genetics or the degree of photoaging predicted response [1][2]. Any such link is therefore untested in these trials.

Injectable GHK-Cu and the FDA

No FDA-approved drug contains GHK-Cu [3]. Non-injectable GHK-Cu is in category 1 of FDA's interim compounding policy [10]; FDA says it generally does not intend to act against compounders for category 1 substances if the conditions in its guidance are met [10]. FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on the bulks list, and no vote has taken place [3]. FDA lists injectable GHK-Cu among withdrawn nominations, stating that compounded injectable drugs containing GHK-Cu may pose a risk of immunogenicity from aggregation and peptide-related impurities, with limited human data to inform safety [5]. Compounded drugs are not FDA-approved [11].

Topical products

Copper peptide creams are sold as cosmetics, which need no FDA approval before sale; claims to treat disease or affect the body's structure or function would make a product a drug [4]. The venous-ulcer trial used a 0.4% copper-complex cream [2]. HealthRX.com offers copper peptide cream as a topical product.